Stimulation of insulin release in the absence of extracellular calcium by isobutylmethylxanthine and its inhibition by somatostatin

L. Mandarino, M. Itoh, W. Blanchard, G. Patton, J. Gerich

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

It has been suggested that somatostatin may inhibit release by interfering with pancreatic islet calcium uptake. To further investigate this hypothesis, the effect of somatostatin on insulin release was examined under conditions where islet uptake of calcium would be unlikely to occur. The phosphodiesterase inhibitor, isobutylmethylxanthine (0.75 mM), was found to stimulate biphasic insulin release from rat pancreases perfused in vitro in the absence of added extracellular calcium on a background of 0.3 mM EGTA and 8 mM glucose; these results support previous suggestions that methylxanthine phosphodiesterase inhibitors may stimulate insulin release by increasing islet cytosol free calcium through translocation of bound (stored) intraislet calcium. Somatostatin (1.0 μM) completely inhibited both phases of isobutylmethylxanthine stimulated insulin release. Since uptake of extracellular calcium by islets was unlikely under the present experimental conditions, these results suggest that somatostatin inhibition of insulin release is probably due to interference with a cAMP dependent translocation of intraislet calcium, or to interference with some other effects of cAMP or an effect of calcium itself rather than to interference with islet calcium uptake.

Original languageEnglish (US)
Pages (from-to)430-433
Number of pages4
JournalEndocrinology
Volume106
Issue number2
StatePublished - 1980
Externally publishedYes

Fingerprint

Somatostatin
Insulin
Calcium
Phosphodiesterase Inhibitors
Biphasic Insulins
Egtazic Acid
Islets of Langerhans
Cytosol
Pancreas
Glucose

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Stimulation of insulin release in the absence of extracellular calcium by isobutylmethylxanthine and its inhibition by somatostatin. / Mandarino, L.; Itoh, M.; Blanchard, W.; Patton, G.; Gerich, J.

In: Endocrinology, Vol. 106, No. 2, 1980, p. 430-433.

Research output: Contribution to journalArticle

Mandarino, L, Itoh, M, Blanchard, W, Patton, G & Gerich, J 1980, 'Stimulation of insulin release in the absence of extracellular calcium by isobutylmethylxanthine and its inhibition by somatostatin', Endocrinology, vol. 106, no. 2, pp. 430-433.
Mandarino, L. ; Itoh, M. ; Blanchard, W. ; Patton, G. ; Gerich, J. / Stimulation of insulin release in the absence of extracellular calcium by isobutylmethylxanthine and its inhibition by somatostatin. In: Endocrinology. 1980 ; Vol. 106, No. 2. pp. 430-433.
@article{0f25f04a294040318958dcaaef20acd4,
title = "Stimulation of insulin release in the absence of extracellular calcium by isobutylmethylxanthine and its inhibition by somatostatin",
abstract = "It has been suggested that somatostatin may inhibit release by interfering with pancreatic islet calcium uptake. To further investigate this hypothesis, the effect of somatostatin on insulin release was examined under conditions where islet uptake of calcium would be unlikely to occur. The phosphodiesterase inhibitor, isobutylmethylxanthine (0.75 mM), was found to stimulate biphasic insulin release from rat pancreases perfused in vitro in the absence of added extracellular calcium on a background of 0.3 mM EGTA and 8 mM glucose; these results support previous suggestions that methylxanthine phosphodiesterase inhibitors may stimulate insulin release by increasing islet cytosol free calcium through translocation of bound (stored) intraislet calcium. Somatostatin (1.0 μM) completely inhibited both phases of isobutylmethylxanthine stimulated insulin release. Since uptake of extracellular calcium by islets was unlikely under the present experimental conditions, these results suggest that somatostatin inhibition of insulin release is probably due to interference with a cAMP dependent translocation of intraislet calcium, or to interference with some other effects of cAMP or an effect of calcium itself rather than to interference with islet calcium uptake.",
author = "L. Mandarino and M. Itoh and W. Blanchard and G. Patton and J. Gerich",
year = "1980",
language = "English (US)",
volume = "106",
pages = "430--433",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Stimulation of insulin release in the absence of extracellular calcium by isobutylmethylxanthine and its inhibition by somatostatin

AU - Mandarino, L.

AU - Itoh, M.

AU - Blanchard, W.

AU - Patton, G.

AU - Gerich, J.

PY - 1980

Y1 - 1980

N2 - It has been suggested that somatostatin may inhibit release by interfering with pancreatic islet calcium uptake. To further investigate this hypothesis, the effect of somatostatin on insulin release was examined under conditions where islet uptake of calcium would be unlikely to occur. The phosphodiesterase inhibitor, isobutylmethylxanthine (0.75 mM), was found to stimulate biphasic insulin release from rat pancreases perfused in vitro in the absence of added extracellular calcium on a background of 0.3 mM EGTA and 8 mM glucose; these results support previous suggestions that methylxanthine phosphodiesterase inhibitors may stimulate insulin release by increasing islet cytosol free calcium through translocation of bound (stored) intraislet calcium. Somatostatin (1.0 μM) completely inhibited both phases of isobutylmethylxanthine stimulated insulin release. Since uptake of extracellular calcium by islets was unlikely under the present experimental conditions, these results suggest that somatostatin inhibition of insulin release is probably due to interference with a cAMP dependent translocation of intraislet calcium, or to interference with some other effects of cAMP or an effect of calcium itself rather than to interference with islet calcium uptake.

AB - It has been suggested that somatostatin may inhibit release by interfering with pancreatic islet calcium uptake. To further investigate this hypothesis, the effect of somatostatin on insulin release was examined under conditions where islet uptake of calcium would be unlikely to occur. The phosphodiesterase inhibitor, isobutylmethylxanthine (0.75 mM), was found to stimulate biphasic insulin release from rat pancreases perfused in vitro in the absence of added extracellular calcium on a background of 0.3 mM EGTA and 8 mM glucose; these results support previous suggestions that methylxanthine phosphodiesterase inhibitors may stimulate insulin release by increasing islet cytosol free calcium through translocation of bound (stored) intraislet calcium. Somatostatin (1.0 μM) completely inhibited both phases of isobutylmethylxanthine stimulated insulin release. Since uptake of extracellular calcium by islets was unlikely under the present experimental conditions, these results suggest that somatostatin inhibition of insulin release is probably due to interference with a cAMP dependent translocation of intraislet calcium, or to interference with some other effects of cAMP or an effect of calcium itself rather than to interference with islet calcium uptake.

UR - http://www.scopus.com/inward/record.url?scp=0018906965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018906965&partnerID=8YFLogxK

M3 - Article

VL - 106

SP - 430

EP - 433

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 2

ER -